Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete … WM Sikov, DA Berry, CM Perou, B Singh, CT Cirrincione, SM Tolaney, ... Journal of clinical oncology 33 (1), 13, 2015 | 1085 | 2015 |
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised … S Loibl, J O'Shaughnessy, M Untch, WM Sikov, HS Rugo, MD McKee, ... The lancet oncology 19 (4), 497-509, 2018 | 699 | 2018 |
Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer SM Wong, RA Freedman, Y Sagara, F Aydogan, WT Barry, M Golshan Annals of surgery 265 (3), 581-589, 2017 | 317 | 2017 |
Internal mammary nodes in breast cancer: diagnosis and implications for patient management—a systematic review RC Chen, NU Lin, M Golshan, JR Harris, JR Bellon Journal of Clinical Oncology 26 (30), 4981-4989, 2008 | 278 | 2008 |
Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis D Calligaris, D Caragacianu, X Liu, I Norton, CJ Thompson, ... Proceedings of the National Academy of Sciences 111 (42), 15184-15189, 2014 | 255 | 2014 |
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients SM Tolaney, Y Boucher, DG Duda, JD Martin, G Seano, M Ancukiewicz, ... Proceedings of the National Academy of Sciences 112 (46), 14325-14330, 2015 | 238 | 2015 |
Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival AC Bafford, HJ Burstein, CR Barkley, BL Smith, S Lipsitz, JD Iglehart, ... Breast cancer research and treatment 115, 7-12, 2009 | 236 | 2009 |
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer … JF De Los Santos, A Cantor, KD Amos, A Forero, M Golshan, JK Horton, ... Cancer 119 (10), 1776-1783, 2013 | 226 | 2013 |
Matched pair analyses of stage IV breast cancer with or without resection of primary breast site B Cady, NR Nathan, JS Michaelson, M Golshan, BL Smith Annals of surgical oncology 15, 3384-3395, 2008 | 205 | 2008 |
Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study Y Sagara, MA Mallory, S Wong, F Aydogan, S DeSantis, WT Barry, ... JAMA surgery 150 (8), 739-745, 2015 | 199 | 2015 |
Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study A Partridge, K Adloff, E Blood, EC Dees, C Kaelin, M Golshan, J Ligibel, ... Journal of the National Cancer Institute 100 (4), 243-251, 2008 | 199 | 2008 |
Impact of neoadjuvant chemotherapy in stage II–III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results … M Golshan, CT Cirrincione, WM Sikov, DA Berry, S Jasinski, TF Weisberg, ... Annals of surgery 262 (3), 434-439, 2015 | 188 | 2015 |
Nomogram for the prediction of having four or more involved nodes for sentinel lymph node–positive breast cancer A Katz, BL Smith, M Golshan, A Niemierko, W Kobayashi, RA Raad, ... Journal of clinical oncology 26 (13), 2093-2098, 2008 | 176 | 2008 |
Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection M Golshan, WJ Martin, K Dowlatshahi The American surgeon 69 (3), 209-212, 2003 | 172 | 2003 |
Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal carcinoma in situ: a population-based … Y Sagara, RA Freedman, I Vaz-Luis, MA Mallory, SM Wong, F Aydogan, ... Journal of Clinical Oncology 34 (11), 1190, 2016 | 153 | 2016 |
Prevention and management of arm lymphedema in the patient with breast cancer. M Golshan, B Smith The journal of supportive oncology 4 (8), 381-386, 2006 | 144 | 2006 |
Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC+/-carboplatin and/or bevacizumab in triple-negative breast cancer … WM Sikov, DA Berry, CM Perou, B Singh, CT Cirrincione, SM Tolaney, ... | 134 | 2016 |
Surgery of the primary tumor does not improve survival in stage IV breast cancer L Dominici, J Najita, M Hughes, J Niland, P Marcom, Y Wong, B Carter, ... Breast cancer research and treatment 129, 459-465, 2011 | 133 | 2011 |
Mucinous breast carcinoma: a large contemporary series CR Barkley, JA Ligibel, JS Wong, S Lipsitz, BL Smith, M Golshan The American journal of surgery 196 (4), 549-551, 2008 | 132 | 2008 |
Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? D Segara, IE Krop, JE Garber, E Winer, L Harris, JR Bellon, R Birdwell, ... Journal of surgical oncology 96 (6), 474-480, 2007 | 128 | 2007 |